slotsofvegasfreespins| Shanghai Lai Shi (002252.SZ): SR604, currently undergoing Phase I clinical studies, is a recombinant protein monoclonal antibody product produced using biosynthetic technology

Gelonghui May 14 丨 Shanghai Lai Shi (002252)(002252slotsofvegasfreespins.SZ) held a performance briefing meeting on May 13, 2024slotsofvegasfreespins,"Does the company have synthetic biology?", The company replied that it is currently conducting phase I clinical studiesslotsofvegasfreespinsSR604 is a recombinant protein monoclonal antibody product produced using biosynthetic technology.